These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 21240683

  • 1. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
    Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, Martellucci I, Migali C, Gotti G, Fiaschi AI, Cozzolino A, Petrioli R.
    Int J Clin Oncol; 2011 Jun; 16(3):264-9. PubMed ID: 21240683
    [Abstract] [Full Text] [Related]

  • 2. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B.
    Ann Oncol; 2007 Jul; 18(7):1165-71. PubMed ID: 17442659
    [Abstract] [Full Text] [Related]

  • 3. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE.
    J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
    [Abstract] [Full Text] [Related]

  • 4. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
    Lipton A, Cook R, Brown J, Body JJ, Smith M, Coleman R.
    Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
    [Abstract] [Full Text] [Related]

  • 5. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
    Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N.
    Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
    [Abstract] [Full Text] [Related]

  • 6. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
    Hu XY, Zou QF, Jin C, Li WD, Chen WS, Ma L.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ, Ma DD, Lv F, Wang JY, Liu Y, Xia WB, Jiang Y, Wang O, Xing XP, Yu W, Li M.
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [Abstract] [Full Text] [Related]

  • 9. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K, Plosker GL.
    Pharmacoeconomics; 2008 Nov; 26(3):251-68. PubMed ID: 18282018
    [Abstract] [Full Text] [Related]

  • 10. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
    Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I, Karamanos NK.
    Int J Cancer; 2009 Oct 01; 125(7):1705-9. PubMed ID: 19521984
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.
    J Bone Miner Res; 2010 Oct 01; 25(10):2239-50. PubMed ID: 20499357
    [Abstract] [Full Text] [Related]

  • 12. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
    Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A, Caraglia M, Holen I.
    Oncol Rep; 2006 May 01; 15(5):1351-7. PubMed ID: 16596210
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
    Kotteas E, Alamara C, Kiagia M, Pantazopoulos K, Boufas A, Provata A, Charpidou A, Syrigos KN.
    Anticancer Res; 2008 May 01; 28(1B):529-33. PubMed ID: 18383897
    [Abstract] [Full Text] [Related]

  • 16. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ.
    Oncol Rep; 2008 Sep 01; 20(3):581-7. PubMed ID: 18695909
    [Abstract] [Full Text] [Related]

  • 17. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.
    Rheumatology (Oxford); 2013 Jun 01; 52(6):1058-69. PubMed ID: 23365149
    [Abstract] [Full Text] [Related]

  • 18. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W.
    Bone; 2007 May 01; 40(5):1238-43. PubMed ID: 17347063
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
    Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J, TUGAMO GROUP.
    Br J Cancer; 2013 Jul 09; 109(1):121-30. PubMed ID: 23799855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.